The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 18 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 123Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 65Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 119Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 66Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 98Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 117Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 60Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 86Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 70Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 126Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,251
Self‐Assembling Multi‐Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma
Li, S., Li, J., Faruque, H. A., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502156 · Cited by 4
Idiopathic Inflammatory Myopathies
Salajegheh, M. K., & Amato, A. A. (2025) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/cont.0000000000001617 · Cited by 4
Disease Monitoring In Multiple Myeloma
Hillengass, J., Martin, T. G., Puig, N., Paiva, B., Usmani, S. Z., Kumar, S. K., & Miguel, J. F. S. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.01.005 · Cited by 5
Self-citationAdvancements and future trends of immunotherapy in light-chain amyloidosis
Mahadevia, H. J., Ponvilawan, B., Sharma, P., Al‐Obaidi, A., Qasim, H., Koyi, J., Anwer, F., & Raza, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103917 · Cited by 4
Terpos, E., Neri, P. E., van de Donk, N. W. C. J., D’Agostino, M., Parekh, S. S., Jagannath, S., Ludwig, H., Avigan, D., Dhodapkar, M. V., & Raje, N. S. (2023) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2023.03.009 · Cited by 4
Self-citationUnderstanding Infection Risk with Anti-BCMA Bispecific Antibodies
Garfall, A. L., & Stadtmauer, E. A. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0157 · Cited by 5
Self-citationMyeloma evades T cell-engaging therapies
Paiva, B., & Miguel, J. F. S. (2023) · Nature Cancer · doi:10.1038/s43018-023-00637-5 · Cited by 4
Self-citationOptions at the time of relapse after anti-BCMA therapy
Razzo, B. M., Garfall, A. L., & Cohen, A. D. (2023) · Hematology · doi:10.1182/hematology.2023000445 · Cited by 4
Self-citationManagement of Newly Diagnosed Multiple Myeloma Today, and in the Future
Devasia, A. J., Lancman, G., & Stewart, A. K. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.007 · Cited by 4
Davis, J. A., McGann, M., Marini, J., & Hashmi, H. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344650 · Cited by 4
“…(biweekly and monthly) teclistamab dosing has also been shown to decrease the incidence of infections while maintaining efficacy and should be considered as a strategy to mitigate infection risk especially considering the risk of infection increases with the chronic nature of BsAb therapy [3,16].”
BackgroundGezer, D., Nogueira, M. S., Kirschner, M., Brümmendorf, T. H., Müller‐Tidow, C., Goldschmidt, H., Raab, M. S., & Giesen, N. (2024) · European Journal Of Haematology · doi:10.1111/ejh.14254 · Cited by 4
How to Identify and Manage High-Risk Smoldering Multiple Myeloma
Mouhieddine, T. H. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01596-5 · Cited by 5
“T cell therapy [53, 54] and bispecific T cell engagers (BiTEs) [55, 56] have led to unprecedented deep and durable responses in relapsed refractory MM.”
Marcoux, C., Pasvolsky, O., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., Ramdial, J., Nieto, Y. L., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.10.011 · Cited by 4
Injection site reaction to teclistamab in a patient with multiple myeloma
Yoon, I. C., Do, N., Vazquez, T., et al. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.10.013 · Cited by 4
Up-Front Treatment of Elderly (Age ≥75 Years) and Frail Patients With Multiple Myeloma
Abdallah, N. H., & Kumar, S. K. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.7039 · Cited by 4
Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
Bruins, W. S. C., Rentenaar, R., Newcomb, J. R., Zheng, W., Ruiter, R. W. J., Baardemans, T., Poma, E., Moore, C., Robinson, G. L., Lublinsky, A., et al. (2024) · HemaSphere · doi:10.1002/hem3.70039 · Cited by 4
Self-citationMancuso, K., Barbato, S., Talarico, M., Tacchetti, P., Zamagni, E., & Cavo, M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2433518 · Cited by 5
Treatment of elderly and frail myeloma patients.
Shih, S., Visram, A., & Mian, H. (2024) · Presse medicale · doi:10.1016/j.lpm.2024.104266 · Cited by 4
Practical insights into bispecific antibody therapy in multiple myeloma
Kawasaki, Y., Winger, S., Esteghamat, N., Rosenberg, A. S., & Beechinor, R. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2445145 · Cited by 4
“…of patients on teclistamab, while no treatment-emergent adverse events led to treatment discontinuation in the RP2D cohort The phase 2 study of MajesTEC-1 included 165 patients who had RRMM after at least three therapy lines that included exposure to an IMiD, a PI, and an anti-CD38 antibody [10].”
InfluentialTesta, U., & Leone, G. G. M. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2025.005 · Cited by 4
“44,45 In a polycentric study of German centers, 123 patients with RRMM, treated with Teclistamab, had an ORR of 52,3% and a PFS of 8,7 months, the 43 patients (36”
An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma
Avigan, Z. M., Rattu, M. A., & Richter, J. R. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2465825 · Cited by 4
“High-grade infections included 12.1% related to COVID-19, 3.6% opportunistic infections, and 9.7% with infection-related deaths (Table 2) [9,21].”
InfluentialImmunotherapy and Cellular Therapies for Cancers in Kidney Transplant Patients
Merzkani, M. A., Attieh, R. M., Jhaveri, K. D., & Murakami, N. (2025) · American Journal of Nephrology · doi:10.1159/000544826 · Cited by 4
Abayasiriwardana, K. S., Wu, L., Laklai, H., Nocula‐Ługowska, M., Tchistiakova, L., Narula, J., Jackson-Fisher, A. J., Golas, J., Lam, M., Grinstein, V., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0379 · Cited by 4
Wonnaparhown, A. M., Hilal, T., Chong, A. C., & Fonseca, R. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101316 · Cited by 4
Rodriguez, C., Rodriguez, T. E., Kentos, A., Driessen, C., Suanmi, K., Lesokhin, A. M., Yee, A. J., Minella, A. C., Maraboina, R., Upreti, V. V., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2528115 · Cited by 4
“[14], elranatamab (any-grade, 73%; grade 2, 17%; grade ≥3, none) [26], talquetamab (any-grade, 77%– 80%; grade 3, 3”
InfluentialGoldfinger, M., Shah, N., & Cooper, D. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2022.6834 · Cited by 2
Considerations for the clinical development of immuno-oncology agents in cancer
Pandiella, A., Calvo, E., Moreno, V., Amir, E., Templeton, A. J., & Ocaña, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1229575 · Cited by 4
“Current approved TCE are designed against well-defined TAA in selected indications, for instance CD3-CD19 bi-specifics including blinatumomab in Philadelphia chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukemia (R/R ALL) (31), and adults and children with B-cell precursor acute lymp…”
BackgroundSzabo, A. G., Thorsen, J., Iversen, K. F., Levring, M. B., Helleberg, C., Hermansen, E., Bønløkke, S. T., Nielsen, K., Teodorescu, E. M., Kurt, E., et al. (2023) · eJHaem · doi:10.1002/jha2.774 · Cited by 4
Zaja, F. F., Lucchini, E., Poiani, M., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27159 · Cited by 4
Multiple myeloma: a paradigm for blending community and academic care
Berdeja, J. G. (2023) · Hematology · doi:10.1182/hematology.2023000431 · Cited by 4
Immune Therapies in AL Amyloidosis—A Glimpse to the Future
Haran, A., Vaxman, I., Gatt, M. E., & Lebel, E. (2024) · Cancers · doi:10.3390/cancers16081605 · Cited by 6
“Teclistamab is a BCMA-CD3 BSA and was the first BSA approved by the FDA for the treatment of r/r MM following the results of the phase 1–2 MajesTEC-1 trial [57].”
Early Detection of Precursor Diseases of Multiple Myeloma
O’Donnell, E., Borden, B. A., & Ghobrial, I. M. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.03.003 · Cited by 4
Willemin, M., Gong, J., Hilder, B. W., Masterson, T. J., Tolbert, J. A., Renaud, T. M., Heuck, C. J., Kane, C. M., Zwart, L. D., Girgis, S., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01093-6 · Cited by 4
“With teclistamab at a single dose of 1.5 mg/kg QW (the RP2D from the MajesTEC-1 study) [44, 46], there was no inhibition of any CYP substrates using the mean IL-6 kinetic profile ( C max 21 pg/mL), which is consistent with talquetamab using the median IL-6 kinetic profile ( C max 18.4 pg/mL and 7.1…”
InfluentialSelf-citationWang, Z., Song, Y., Guo, H., Yan, Y., Ma, L., & Liu, B. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01290-z · Cited by 3
“The aim of the MajesTEC-1 study [34, 35] was to evaluate the safety, tolerability, and preliminary efficacy of teclis-tamab in 165 patients with RRMM.”
BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects
Amin, R., Dey, B. K., Ronald Darwin, C., Cho, W. C. S., Sharifi‐Rad, J., & Călina, D. C. (2025) · Medical Oncology · doi:10.1007/s12032-025-02753-x · Cited by 6
BCMA CAR-T: From Multiple Myeloma to Light-Chain Amyloidosis
Lewis, E., & Jimenez-Zepeda, V. H. (2025) · Current Oncology · doi:10.3390/curroncol32080418 · Cited by 4
“Its approval for RRMM was based on data from the MajesTEC trial [39,40].”
Liegel, J. J., Stroopinsky, D., Cheloni, G., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015449 · Cited by 3
Baljević, M., Schiller, G. J., Mark, T. M., Domelen, D. R. V., & Gasparetto, C. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1649493 · Cited by 4
Talarico, M., Barbato, S., Maisnar, V., Delimpasi, S., Puppi, M., Rizzello, I., Pantani, L., Tacchetti, P., Martello, M., Vigliotta, I., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06326-3 · Cited by 4
Dye, B., Gromer, D. J., Bibi, M., Siegrist, E. A., & Sassine, J. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.007 · Cited by 3
Incorporating mRNA therapeutics into biological treatments of hematologic malignancies
Hunia, J., Tomasik, J., Czerwik, N., Pezeshki, P. S., & Nowis, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680071 · Cited by 6
Sheu, M., Garcia, S. M., Patel, M. H., et al. (2025) · Oncology · doi:10.1159/000548964 · Cited by 3
Rahbari, K. J., del Toro-Mijares, R., Kennedy, K., Mader, L., Sengsayadeth, S. M., Jayani, R., Jerkins, J. H., Jallouk, A. P., Kim, T. K., Bhaskar, S., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00652 · Cited by 3
Rodríguez‐Otero, P., Moreau, P., Mateos, M., Krauth, M. T., Rasche, L., Kastritis, E., Oriol, A., Zamagni, E., Albrecht, C., Rubio‐Azpeitia, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.003 · Cited by 4
Self-citationReshaping multiple myeloma treatment: recent breakthroughs
Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 4
“In contrast, BsAbs offer more immediate, off-the-shelf availability but are associated with a substantial hospitalization burden due to mandatory step-up dosing and intensive monitoring for CRS, particularly during early treatment cycles [61].”
Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit
Rodriguez, C., Touzeau, C., Crusoé, E. D. Q., Pericole, F. V., & Hungria, V. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.015 · Cited by 3
Akiyama, H., Kakiuchi, S., Sakamoto, A., Tomigaki, N., Fujioka, S., Harima, I., Niwa, R., Takagi, I., Kozuki, Y., Miyata, Y., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1705843 · Cited by 4
Consensus guidelines for antibacterial prophylaxis in patients with neutropenia
Lindsay, J., Yeoh, D. K., Teh, B. W., Reynolds, G. K., Henden, A. S., McQuilten, Z., Wheeler, M., Hamilton, A., Nelson, A. C., Nakagaki, M., et al. (2025) · Internal Medicine Journal · doi:10.1111/imj.70250 · Cited by 3
“68,69,73,83 Therefore, the impact of antibacterial prophylaxis (if used) on infection rates or mortality cannot be adequately evaluated using available data from published clinical trials of these new-generation therapies.”
Paulsen, J. S., & Slørdahl, T. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1722579 · Cited by 4
“Frerichs et al. (13) studied the effect of IgRT in a cohort (n = 52) of relapsed refractory (RR) MM patients receiving teclistamab in the MajesTEC-1 trial (6).”
Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab
Tomkins, O. M., Maamari, R. G., Douthwaite, S. T., Roy, A., Bain, H., Kohli, N., de Lavallade, H., Kazmi, M. A., Sachchithanantham, S., Dmello, T., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.01.017 · Cited by 4
Xin, X., Fan, C., Sheng, R., Li, X. C., Zhu, X., Huang, Y., Seraji, H. R., Urazbaeva, D., Atamuratova, Z., & Ubaydullaevna, A. D. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02050-5 · Cited by 4
“…deep and durable responses in heavily pretreated MM In MajesTEC-1 trial, the BCMA/CD3 bispecific teclistamab achieved an overall response rate (ORR) of 63%, with CRs in 39% and MRD negativity in nearly half of responders, leading to its FDA approval as the first bispecific antibody for MM [204 ].”
Marneni, N., Lessans, S., Dholaria, B., Sengsayadeth, S. M., Biltibo, E. A., Patel, V. G., Bhaskar, S., Jayani, R., Mohan, S. R., Kishtagari, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1721820 · Cited by 3
The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma
Barachini, S., Cassano, R. C., Ronca, F., Petrini, I., Galimberti, S., & Buda, G. (2026) · European Journal Of Haematology · doi:10.1111/ejh.70168 · Cited by 3
Hamadeh, I. S., Merz, M., Derkach, A., Modelevsky, L. R., Lesokhin, A. M., Mailankody, S., Hultcrantz, M. L., Tan, C. R. C., Hassoun, H., Shah, U., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.03.016 · Cited by 3
Self-citationLee, H. C., Plattel, W. J., Harrison, S. J., Sborov, D. W., Lentzsch, S., Spencer, A. G., Niesvizky, R., Trudel, S., Mollee, P. N., Vij, R., et al. (2026) · Blood · doi:10.1182/blood.2025032044 · Cited by 4
Larue, M., Bitoun, S., Zuber, J., Michel, M., & Talbot, A. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104060 · Cited by 5
How I treat plasma cell leukemia
Hadidi, S. A., van Rhee, F., & Anderson, L. D. (2026) · Blood · doi:10.1182/blood.2025032145 · Cited by 4
Rejeski, K., Banerjee, R. K., & Hill, J. A. (2026) · Blood · doi:10.1182/blood.2025032298 · Cited by 3
LeBlanc, R., Mian, H., Reece, D., Su, J.-D., Masih-Khan, E., Chu, M. P., Jimenez-Zepeda, V., Sebag, M., Song, K., Louzada, M., et al. (2023) · European Journal of Haematology · doi:10.1111/ejh.14082 · Cited by 2
Treatment sequences and drug costs from diagnosis to death in multiple myeloma
Seefat, M. R., Cucchi, D. G. J., Groen, K., Donker, M. L., Hem, K. G. V. D., Westerman, M., Gerrits, A. M., Beeker, A., van de Donk, N. W. C. J., Blommestein, H. M., et al. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14119 · Cited by 3
Self-citationTeipel, R., Rieprecht, S., Trautmann‐Grill, K., Röllig, C., Klötzer, C., Zimmer, K., Rathaj, G., Bach, E., Brückner, M., Heyn, S., et al. (2023) · Transfusion · doi:10.1111/trf.17566 · Cited by 3
Exploring the High-Grade and Refractory Neurotoxicity of Teclistamab: An Underreported Entity
Lutfi, F. U., Abdallah, A.-O. A., Nashatizadeh, M. M., Ahmed, N., Nelson, M., Hamideh, J., Mahmoudjafari, Z., & Shune, L. O. (2023) · Cureus · doi:10.7759/cureus.49192 · Cited by 4
“These findings led to FDA approval for treatment in RRMM [2,3].”
BackgroundMateos, M.-V., Weisel, K., Diels, J., Arribas, A., Tamayo, M., Schecter, J., Roccia, T., Haddad, I., Pacaud, L., & Moreau, P. (2023) · Clinical Lymphoma, Myeloma & Leukemia · doi:10.1016/j.clml.2023.12.001 · Cited by 2
Self-citationNew Therapies on the Horizon for Relapsed Refractory Multiple Myeloma
Abdallah, N. H., & Kumar, S. K. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.12.013 · Cited by 3
Howard, A. J., Concepcion, I., Wang, A. X., Hamadeh, I. S., Hultcrantz, M. L., Mailankody, S., Tan, C. R. C., Korde, N., Lesokhin, A. M., Hassoun, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012871 · Cited by 3
Self-citationHydren, J. R., Lin, D., Sweeney, N. W., et al. (2024) · Frontiers in Health Services · doi:10.3389/frhs.2024.1354760 · Cited by 3
AL amyloidosis: an overview on diagnosis, staging system, and treatment
Morè, S., Manieri, V. M., Corvatta, L., et al. (2024) · Frontiers in Hematology · doi:10.3389/frhem.2024.1378451 · Cited by 3
Improving Access to T-Cell Therapies in Multiple Myeloma
Derman, B. A. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.06.011 · Cited by 3
Dave, F., Vaghela, P., Heath, B., Dunster, Z., Dubinina, E., Thakker, D., Mann, K., Chadwick, J., Cane, G., Kaira, B. G., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0187 · Cited by 3
“2, 3).”
Bandaru, S. S., Multani, N. S., Nauam, W. T., & Benitez-Farina, C. (2024) · Case Reports in Oncology · doi:10.1159/000540979 · Cited by 3
“The function of this speci fi c antibody treatment is to bring the patient ’ s own T cells in close proximity to myeloma cells, allowing for B-cell immune activation and destruction of the myeloma cells [4].”
InfluentialPeery, M. R., Hill, H., Sharps, A., et al. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241282115 · Cited by 3
Supimon, K., Sangsuwannukul, T., Luangwattananun, P., & Yenchitsomanus, P. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113480 · Cited by 7
von Bahr, L., Strang, P. M., Schultz, T., et al. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.42189 · Cited by 3
Challenges in Multiple Myeloma Therapy in Older and Frail Patients
Aureli, A., Marziani, B., Sconocchia, T., Pasqualone, G., Franceschini, L., Spagnoli, G. C., Venditti, A., & Sconocchia, G. (2025) · Cancers · doi:10.3390/cancers17060944 · Cited by 3
Watson, E. C. R., Djebbari, F., Panitsas, F. P., Vallance, G. D., Asher, S., Saeed, M., Walker, M., Powell, M., Rampotas, A., Leary, H., et al. (2025) · eJHaem · doi:10.1002/jha2.70039 · Cited by 2
“Even before the DREAMM-3 result, belamaf’s efficacy as a BCMA-targeting agent had been overshadowed by ORRs from BCMA-targeting CAR T and bispecific antibodies (bsAbs) in non-randomised Phase 2 trials [8–10].”
Self-citationTalbot, A., Hulin, C., Perrot, A., Macro, M., Merzoug, K. B., Mohty, M., Bobin, A., Karlin, L., Manier, S., Vincent, L., et al. (2025) · Clinical Lymphoma, Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.015 · Cited by 3
Self-citationCurrent and Future Directions of Immunotherapies in Multiple Myeloma
Biltibo, E. A., Surapaneni, M., Hadidi, S. A., Suvannasankha, A., & Jayani, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473316 · Cited by 4
Cheema, M. A., Syed, S., & GHUMAN, Z. (2025) · Archive of Clinical Cases · doi:10.22551/2025.47.1202.10320 · Cited by 3
“Teclistamab, a fully humanized IgG4 bispecific antibody targeting B-cell maturation antigen (BCMA), is approved for refractory multiple myeloma, demonstrating a 63% response rate ( X complete response) in 39.4% of patients at a median 14.1-month follow-up [5].”
InfluentialMoore, S. E., Miller, H., Parrish, C., Seymour, F., Miller, L. J., Chandler, T., Land, J., Karpha, I., Brearton, G., Thompson, S., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.70041 · Cited by 4
“76,77 In the MagnetisMM-3 and MajesTEC 1 studies, all grade infections occurred in 69.9% and 76.4%, respectively, with 39.8% and 44.8%, respectively, experiencing grade 3–4 events.”
InfluentialKikuchi, J., Osada, N., Matsuoka, S., Yasui, H., Furukawa, Y., & Nakasone, H. (2025) · Leukemia · doi:10.1038/s41375-025-02792-3 · Cited by 3
“Furthermore, the ORR of Tec was reduced in patients with high tumor burden as measured by bone marrow plasma cells (BM-PCs) > 60%, whereas those of Elra were >50% [8, 9].”
Multi-hit TP53 confers the poorest survival in multiple myeloma in the era of novel therapies
Nesnadna, R., Petráčková, A., Minařík, J., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01392-2 · Cited by 3
“…with TP53 mut but without del(17p), as they will not be correctly risk stratified and are thus less likely to be prioritised for novel therapies within trials or for earlier or optimised therapeutic intervention (Berdeja et al. 2021; Moreau et al. 2022; Munshi et al. 2021; Pas-volsky et al. 2023).”
Identification and Targeting of Mutant Neoantigens in Multiple Myeloma Treatment
Brancati, V. U., Minutoli, L., Marini, H. R., Puzzolo, D., & Allegra, A. (2023) · Current Oncology · doi:10.3390/curroncol30050348 · Cited by 3
“In the first one [50], 165 RRMM patients treated with JNJ64007957 teclistamab were evaluated, reporting 63% OR at 14.”
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
Beck, K., Sandahl, T. B., Ailawadhi, S., Khera, N., & Jensen, C. J. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00705-8 · Cited by 3
Casey, M., Lee, C., Hoyte, S. M., Johnston, R. L., Kwok, W. Y., Law, S. C., Gandhi, M. K., Harrison, S. J., & Nakamura, K. (2024) · Haematologica · doi:10.3324/haematol.2023.284435 · Cited by 4
Pharmacist perspectives on emerging T cell–engaging bispecific therapies in cancer therapeutics
Moore, D. C., Digiantonio, N., Oxencis, C. J., & Taucher, K. D. (2024) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxae050 · Cited by 3
Cords, L., Schaefers, C., Kamili, A., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284917 · Cited by 3
“1 In the phase I-II MajesTEC-1 study, teclistamab induced deep and durable responses with manageable toxicity, 2 and its high efficacy compared to the standard of care in RRMM highlights its clinical relevance.”
BackgroundMatsunaga, N., Suzuki, T., Nishitarumizu, N., Nakanishi, Y., Kondo, A., Kato, Y., Ebina, T., Marumo, Y., Nakamura, T., Nakashima, T., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.03.012 · Cited by 3
Catamero, D., Benito, P. B., Shenoy, S., Doyle, M., Fowler, J., Kobos, R., Banerjee, A., & Kruyswijk, S. (2024) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2024.151621 · Cited by 3
Self-citationHashmi, H., Kumar, A., Kharfan-Dabaja, M., Munshi, P., Inamoto, Y., DeFilipp, Z. M., Dholaria, B. R., Jain, T., Perales, M.-A., Carpenter, P., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.04.007 · Cited by 3
Self-citationResearch strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance
Yang, J., Yu, Y., Wang, Z., Li, Q.-Q., Ding, N., Leng, X., Cai, J., Zhang, M., Wang, J., Zhou, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116435 · Cited by 3
Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
Reed, D. R., & Lum, L. G. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2384086 · Cited by 4
“Elimination of plasma cells leads to hypogammaglobuli-nemia and increased risk of infection which is a class toxicity for BsAb therapies, especially in multiple myeloma [35].”
Akhtar, O. S., Szabó, A., Bhatlapenumarthi, V., Forsberg, M., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19700 · Cited by 4
A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
Goldsmith, S., Slade, M. J., Fiala, M., Harding, M., Crees, Z., Schroeder, M. A., Stockerl-Goldstein, K., & Vij, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05975-7 · Cited by 4
McCurdy, A. B. R., Reece, D. E., Louzada, M., White, D. J., Parkin, S., Chu, M. P., Kotb, R. R., Mian, H. S., Othman, I., Su, J., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01135-2 · Cited by 4
Cellular and immunotherapies for myelodysplastic syndromes
Stubbins, R. J., Cherniawsky, H. M., & Karsan, A. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.09.006 · Cited by 3
Saba, L., Fu, C., Liang, H., & Chaulagain, C. P. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.006 · Cited by 3
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma
Saied, G., & Halford, Z. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241281742 · Cited by 3
Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma
Marable, M., Kelly, K., Cooperrider, J. H., Jakubowiak, A. J., & Derman, B. A. (2024) · eJHaem · doi:10.1002/jha2.1039 · Cited by 3
Lancman, G., Song, K., White, D., Crosbie, T., Sharif, I., Emond, M., Raza, M. S., Elias, M., Kaedbey, R., & Chu, M. P. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1446995 · Cited by 3
Teclistamab as Successful Treatment of Relapsed TEMPI Syndrome
Sykes, D. B., & Schroyens, W. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2411016 · Cited by 3
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
